Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.43 |
| ▸ | FEN1 | P39748 | 8/20 | 0.43 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442141 | 1.00 | NSD2 (0.47) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL16937299 | 0.85 | NSD2 (0.39) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2803354 | 0.82 | NSD2 (0.58) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL29958156 | 0.81 | CYP1A2 (0.49) | SMN1; SMN2LMNAALOX5APFEN1ALDH1A1 | |
| SCHEMBL344268 | 0.81 | CYP1A2 (0.49) | SMN1; SMN2LMNAALOX5APFEN1ALDH1A1 | |
| SCHEMBL6166172 | 0.77 | ALDH1A1 (0.44) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1111419 | 0.77 | NSD2 (0.50) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL29953983 | 0.76 | CA12 (0.47) | SMN1; SMN2KDM4ELMNAHPGDKMT2A | |
| SCHEMBL959477 | 0.76 | NSD2 (0.46) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL27584595 | 0.76 | NSD2 (0.43) | NSD2MAPTSMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | REPARE THERAPEUTICS INC. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-114174292-B | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors | 修复治疗公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2023283256-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-0711162-A1 | IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| US-5436259-A | Angiotensive II antagonist as hypotensive agents | MERCK & CO., INC. (US) | 1995-07-25 | — | — | US | disclosed |
| US-5411980-A | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5395844-A | Hypotensive agents; congestive heart failure | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| US-5389635-A | 4- or 5-heterocyclic substituted imadazoles as angiotensin-II antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1994028896-A1 | IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5281614-A | Hypotensive agents, glaucoma or angiotensin antagonists | MERCK & CO., INC. (US) | 1994-01-25 | — | — | US | disclosed |
| US-5262412-A | Angiotensin II antagonists, hypotensive agents, treatment of congestive heart failure and glaucoma | MERCK & CO., INC. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5219856-A | Angiotensin-II antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | NSD2 1827/4885MAPT 1485/4885SMN1; SMN2 239/4885 |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | NSD2 2883/4885MAPT 1945/4885SMN1; SMN2 1026/4885 |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | NSD2 639/4885MAPT 3617/4885SMN1; SMN2 4581/4885 |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | NSD2 1827/4885MAPT 1485/4885SMN1; SMN2 239/4885 |
| US-11851422-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | NSD2 1827/4885MAPT 1485/4885SMN1; SMN2 239/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | NSD2 1827/4885MAPT 1485/4885SMN1; SMN2 239/4885 |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | ATR, CHEK2, CHEK1 | NSD2 2883/4885MAPT 1945/4885SMN1; SMN2 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.